Prosecution Insights
Last updated: November 04, 2026
Application No. 17/765,418

NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE THEREOF

Non-Final OA §112
Filed
Mar 30, 2022
Priority
Oct 01, 2019 — provisional 62/908,954 +1 more
Examiner
TOWNSLEY, SARA ELIZABETH
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rapafusyn Research And Development Inc.
OA Round
2 (Non-Final)
26%
Grant Probability
At Risk
2-3
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants only 26% of cases
26%
Career Allowance Rate
105 granted / 401 resolved
-33.8% vs TC avg
Strong +48% interview lift
Without
With
+48.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
74 currently pending
Career history
468
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
41.7%
+1.7% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
26.5%
-13.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 401 resolved cases

Office Action

§112
NON-FINAL REJECTION Receipt is acknowledged of Applicants' Amendments and Remarks, filed Feb. 25, 2026 and Jun. 25, 2026. Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The rejections and/or objections set forth below are either maintained or newly applied, and constitute the complete set presently applied to the instant claims. STATUS OF THE CLAIMS Claims 14, 15, and 18-33 have been canceled. Claim 1 has been amended and incorporates no new matter. No new claims have been added. Claims 9-13, 16, 17, and 34-44 stand withdrawn as drawn to nonelected inventions and/or species. Thus, claims 1-8 now represent all claims currently pending and under consideration. INFORMATION DISCLOSURE STATEMENT The information disclosure statements (IDS) submitted on Feb. 25, 2026 and May 12, 2026 were filed after the mailing date of the non-final action on Oct. 2, 2025. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. RESPONSE TO ARGUMENTS Applicant’s amendments overcome the rejections under 35 U.S.C. § 103 over Liu et al. (WO2017/136708) in view of Meanwell (2018); and on the ground of obviousness-type double patenting over claim 2 of U.S. Patent No. 11,708,391 in view of Meanwell (2018). Therefore, these rejections are withdrawn. NEW REJECTIONS Claim Rejections - 35 U.S.C. § 112(d) – Improper Dependency The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. 1. Claim 2 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Specifically, claim 2 reads as follows: PNG media_image1.png 124 696 media_image1.png Greyscale However, this limitation fails to further limit claim 1, because the indicated carbon atom is chiral, which will, of necessity, be in either the R or S configuration. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. 2. Claims 6 and 7 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Specifically, claim 6 is drawn to the compound of claim 3, wherein the compound “is an inhibitor of macrophage migration inhibitory factor (MIF) nuclease activity and an inhibitor of parthanatos mediated cell death.” Similarly, claim 7 is drawn to the compound of claim 3, wherein the compound “is an inhibitor of parthanatos mediated cell death.” However, these recitations fail to further limit claim 3. As evidenced by the specification (Table 4), the recited properties are intrinsic to compound 121 as recited by claim 3. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 1, 3-5, and 8 are allowed. Reasons for Allowance Liu et al. (WO 2017/136708, of record) disclose compounds of generic formula (E) (paras. [0007], [0017]), and teach and suggest a compound having the structural formula: Compound of Liu et al. Claimed Formula (VII) PNG media_image2.png 316 430 media_image2.png Greyscale PNG media_image3.png 272 448 media_image3.png Greyscale which falls within the scope of claimed formula (VII), except for the fluorine at R2. Liu et al. do not disclose, teach, or suggest that the phenyl ring (circled) can be substituted by fluorine, as required by claim 1. The compounds of Liu et al. contain approximately 81 possible fluorination sites; and Liu et al. suggest that many of these sites may be halogenated. However, none of the compounds exemplified by Liu et al. contain a fluorine; nor do Liu et al. suggest a halogen substituent specifically at position R2 of formula (VII), or anywhere on the same phenyl ring. Thus, Liu et al. do not provide any guidance as to which particular site would be beneficial to fluorinate; nor does Meanwell (J. Med. Chem. 61, 5822-5880 (2018), of record) disclose, teach, or suggest any particular sites to favor over others for fluorination. CONCLUSION Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARA E. TOWNSLEY whose telephone number is 571-270-7672. The examiner can normally be reached on Mon-Fri from 10:00 am to 6:00 pm (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeff S. Lundgren, can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SARA E. TOWNSLEY/Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Mar 30, 2022
Application Filed
Oct 02, 2025
Non-Final Rejection mailed — §112
Feb 25, 2026
Response Filed
Jun 25, 2026
Response Filed
Sep 28, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12729210
CRYSTAL FORMS OF PYRIDOPYRAZOLE COMPOUNDS AND PREPARATION METHOD THEREFOR
3y 5m to grant Granted Sep 08, 2026
Patent 12692261
SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF
3y 6m to grant Granted Jul 28, 2026
Patent 12662475
DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS
3y 8m to grant Granted Jun 23, 2026
Patent 12662483
COCRYSTALLINE FORMS OF FGFR3 INHIBITORS
2y 9m to grant Granted Jun 23, 2026
Patent 12643913
MCL-1 INHIBITOR FORMULATIONS
3y 3m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
26%
Grant Probability
75%
With Interview (+48.4%)
3y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 401 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month